2015-12-30-世界卫生组织-Meeting_of_the_Pandemic_Influenza_Preparedness_Framework_Advisory_Group,_15-16_October_2015_9页_328kb

Meeting Summary: MEETING OF THE PANDEMIC INFLUENZA PREPAREDNESS FRAMEWORK (PIPF) ADVISORY GROUP, 15-16 October 2015, Geneva

1. Updates and Recommendations on SMTA2 Agreements

• The Secretariat reported ongoing negotiations for Standard Material Transfer Agreements 2 (SMTA2s), noting challenges in balancing reasonable benefit-sharing.
• Recommendations to Director-General (DG):
  • Use a stepwise approach (informal/formal communications, government dialogues, senior official interventions) to remind manufacturers of unreasonable positions during SMTA2 talks, including potential suspension of access to PIP Biological Materials (PIP BM).
  • Negotiate benefit-sharing commitments based on 10% of annual sales, allowing flexibility; retain the right to request monetary or in-kind contributions during a pandemic.

2. Partnership Contribution (PC) Management

• Progress in collecting PC funds (2012–2015) was mixed; cooperation from manufacturers was noted despite lingering issues (outstanding funds, declining questionnaire responses).
• Next Steps: Prioritize strengthening interactions with industry associations, reviewing sales band calculations, and refining PC Annual Reports with improved indicators and transparency.
• Objectives: Increase the number of PC recipient countries and scale up activities in all areas.

3. Virus Sharing and Genetic Sequence Data (GSD) Handling

• While influenza virus sharing has increased since PIPF adoption, recent trends show a decrease. Stakeholders highlighted logistical challenges in shipping viruses.
• Recommendations to DG:
  • Remind Member States to promptly provide PIP BM (H5N1 and other pandemic-potential viruses) to WHO-designated centers, ensuring inter-ministerial coordination.
  • Reinforce that GSD alone does not satisfy sharing obligations under the Framework.
• GSD Update: A Technical Working Group focused on optimizing GSD sharing systems and monitoring usage in products.

4. 2016 PIPF Framework Review and Other Topics

• The Advisory Group prepared a separate report for the 2016 Review, emphasizing alignment with ongoing pandemic preparedness efforts and caution against undertaking unfinished GAP work outside PIP scope.
• Other discussions addressed communications materials (e.g., revised PIPF Q&A, SMTA2 fact sheet), the PIVI proposal, and the value of regional offices in fostering transparency.

5. Conclusions and Follow-Up

• Key Developments: Four-decade low in candidate vaccine virus development and sharing noted.
• Outcomes: Identified the need for sustained engagement on SMTA2 negotiations, PC recovery, and improved communications.
• Next Meeting: Set for 11 April 2016.

6. Transparency and Process Refinements

• Member declarations of interest were reviewed, with transparency maintained throughout the process.
• Opportunities identified to enhance PC collection efficiency and the overall implementation framework.